Drug-loaded core-shell microspheres for sequence regulation of cell autophagy and cartilage generation, and preparation method and application of drug-loaded core-shell microspheres

By using the drug-loaded core-shell microspheres with core-shell structures in the treatment of osteoarthritis, the differential release of chondrocyte autophagy activity and chondrogenic drugs was achieved, solving the problem of poor regulation of single autophagy, and improving the Cartilage repair ability and therapeutic effect.

CN118903058APending Publication Date: 2024-11-08DONGHUA UNIV
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202410964082.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, when treating osteoarthritis, a single autophagy regulation drug is difficult to achieve satisfactory therapeutic effects, and the joint cartilage repair ability is limited, resulting in the gradual aggravation of OA disease.

Method used

Using drug-carrying core-shell microspheres with core-shell structure, the shell contains a polymer matrix with photocrosslinking properties and the first drug-carrying nanoparticles that support the active drug for autophagy of chondrocytes, and the core layer contains a water-soluble polymer matrix. and the second drug-loaded nanoparticles targeting the modification of cartilage matrix molecules, the bilayer structure microspheres are formed through a microfluidic chip to regulate the autophagy activity of chondrocytes and the differential release of pro-chondrogenic drugs.

Benefits of technology

It improves the retention time and bioavailability of the drug in the joint cavity, effectively regulates the autophagy activity of chondrocytes and promotes cartilage repair, and significantly improves the therapeutic effect of cartilage degeneration in osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004951232200000011
    Figure HDA0004951232200000011
  • Figure HDA0004951232200000012
    Figure HDA0004951232200000012
  • Figure HDA0004951232200000021
    Figure HDA0004951232200000021
Patent Text Reader

Abstract

The invention provides a drug-loaded core-shell microsphere for sequence regulation of cell autophagy and chondrogenesis, the drug-loaded core-shell microsphere is provided with a shell layer and a core layer in sequence from outside to inside, and the shell layer comprises a polymer matrix with a photo-crosslinking characteristic and first drug-loaded nanoparticles loaded with a drug for regulating chondrocyte autophagy activity; and the core layer comprises a water-soluble polymer matrix, and second drug-loaded nano particles which are modified by targeting cartilage matrix molecules and are loaded with a drug for promoting cartilage generation. The invention also provides a preparation method of the drug-loaded core-shell microspheres for sequence regulation of cell autophagy and cartilage generation. The invention further provides application of the drug-loaded core-shell microspheres for sequence regulation of cell autophagy and cartilage generation in drugs for treating osteoarthritis cartilage degeneration diseases. According to the drug-loaded core-shell microsphere for sequence regulation of cell autophagy and cartilage generation and the preparation method and application thereof, the residence time of a drug in an articular cavity is prolonged, the bioavailability of the drug in the articular cavity is improved, the cartilage cell activity is effectively improved, and cartilage repair is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedical engineering, and relates to a drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, and a preparation method and application thereof, and specifically relates to a drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, and a preparation method thereof, and application thereof in a drug for treating osteoarthritis cartilage degeneration diseases. Background Art

[0002] Osteoarthritis (OA) is a common clinical chronic degenerative joint disease, with the main pathological features of articular cartilage degeneration, subchondral bone sclerosis, synovial lesions and osteophyte formation, which seriously affect the patient's motor function and quality of life. Due to the lack of nerves and blood vessels, articular cartilage is difficult to complete self-repair after cartilage damage. Cartilage degeneration is an important factor in the pathogenesis of OA, and maintaining the health of chondrocytes can inhibit the development of OA. At present, intra-articular injection of drugs is one of the effective means of clinical treatment of OA. Cell autophagy is a self-protective response of cells after stress stimulation. It plays an important role in defending against a variety of adverse external factors. It can clean up and degrade damaged organelles and intracellular macromolecules and recycle them to maintain cell metabolism. Previous studies have found that when chondrocytes are damaged, the apoptosis process leads to the degeneration of articular cartilage, and autophagy plays a key regulatory role in inhibiting the initiation of chondrocyte apoptosis, thereby slowing down the pathological process of OA. Therefore, restoring the level of chondrocyte autophagy through drugs has become a new strategy to delay articular cartilage degeneration.

[0003] During the course of OA, the integrity of the cartilage structure is destroyed, the balance between the synthesis and degradation of the articular cartilage matrix is ​​broken, and then apoptosis, chondrocyte hypertrophy and vascular infiltration of the subchondral bone occur. Due to the limited self-repair ability of articular cartilage, the original structure and function of articular cartilage cannot be restored after damage, resulting in the gradual aggravation of OA. Therefore, restoring the integrity and function of articular cartilage plays an important role in delaying or even reversing the progression of OA. Many drugs that promote cartilage formation are used to repair cartilage damage, such as Kartogenin (KGN), chondroitin sulfate, transforming growth factor-β, etc. KGN is a small heterocyclic drug compound that can effectively promote the differentiation of mesenchymal stem cells into chondrocytes, achieve the repair and regeneration of articular cartilage, and show good therapeutic effects in a variety of OA animal models. However, based on a single autophagy regulation, satisfactory OA treatment effects cannot be obtained, and the construction of a multi-drug release system with different regulatory effects will improve the effectiveness of OA treatment. Summary of the invention

[0004] In view of the shortcomings of the prior art mentioned above, the purpose of the present invention is to provide a drug-loaded core-shell microsphere for sequence regulation of cell autophagy and chondrogenesis, and a preparation method and application thereof. According to the drug-loaded core-shell microsphere for sequence regulation of cell autophagy and chondrogenesis with a core-shell structure, an attempt is made to construct a multi-drug release system for joint cavity injection for the co-delivery and differential release of the two drugs, taking into account both the induction of cartilage autophagy to restore cellular homeostasis and the promotion of cartilage damage repair, so as to obtain a better OA treatment effect through the synergistic effect of restoring the autophagic activity of chondrocytes and promoting chondrogenesis.

[0005] To achieve the above-mentioned purpose and other related purposes, the first aspect of the present invention provides a drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, which comprises a shell layer and a core layer from the outside to the inside, wherein the shell layer comprises a polymer matrix having photo-crosslinking properties and a first drug-loaded nanoparticle loaded with a drug for regulating chondrocyte autophagy activity, and the core layer comprises a second drug-loaded nanoparticle containing a water-soluble polymer matrix, targeted cartilage matrix molecular modification and a drug for promoting chondrogenesis, wherein the release rate of the drug for regulating chondrocyte autophagy activity is faster than the release rate of the drug for promoting chondrogenesis.

[0006] The second aspect of the present invention provides a method for preparing drug-loaded core-shell microspheres for sequence regulation of cell autophagy and chondrogenesis, comprising the following steps:

[0007] 1) loading a drug that regulates chondrocyte autophagy activity into a first drug-loaded nanoparticle, and uniformly mixing the obtained first drug-loaded nanoparticle loaded with the drug that regulates chondrocyte autophagy activity with a polymer matrix having photo-crosslinking properties in a solvent to obtain a shell layer solution; and / or, modifying a second drug-loaded nanoparticle with targeted cartilage matrix molecules, and loading a chondrogenesis drug into the second drug-loaded nanoparticle, and uniformly mixing the obtained second drug-loaded nanoparticle modified with targeted cartilage matrix molecules and loaded with a chondrogenesis-promoting drug with a water-soluble polymer matrix in a solvent to obtain a core layer solution;

[0008] 2) using a microfluidic chip, respectively passing a shell layer solution and a core layer solution into different flow channels to form a shell layer channel and a core layer channel, then mixing the shell layer solution in the shell layer channel with the core layer solution in the core layer channel to form a core-shell solution located in a continuous phase channel, and passing an oily substance into the continuous phase channel to form a double-layer structure microsphere having a shell layer and a core layer in sequence from the outside to the inside of the core-shell solution, so that the release rate of the drug regulating the autophagy activity of chondrocytes in the shell layer solution is faster than the release rate of the drug promoting chondrogenesis in the core layer solution;

[0009] 3) The double-layer structure microspheres are irradiated with a blue light source for photocuring to provide drug-loaded core-shell microspheres.

[0010] The third aspect of the present invention provides a drug-loaded core-shell microsphere for sequence regulation of cell autophagy and chondrogenesis, which is prepared by the above method.

[0011] The fourth aspect of the present invention provides the use of the above-mentioned drug-loaded core-shell microspheres with a sequence regulating cell autophagy and chondrogenesis in the preparation of drugs for treating osteoarthritis cartilage degeneration diseases.

[0012] As described above, the drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis provided by the present invention and their preparation method and application have the following beneficial effects:

[0013] (1) The present invention provides a drug-loaded core-shell microsphere that sequentially regulates cell autophagy and cartilage formation, and a preparation method and application thereof. The drug-loaded core-shell microsphere prepared by the microsphere has excellent biocompatibility, and the drug-loaded core-shell microsphere of appropriate size can be smoothly injected into the joint cavity, thereby improving the retention time and bioavailability of the drug in the joint cavity.

[0014] (2) The present invention provides a drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, as well as a preparation method and application thereof. Through the differential release of drugs in the shell layer and the core layer of the drug-loaded core-shell microsphere, the autophagic activity of chondrocytes can be sequentially regulated and chondrogenesis can be promoted, thereby effectively improving chondrocyte activity and promoting cartilage repair. It has application value in the treatment of osteoarthritis cartilage degeneration and can be used as a drug for the treatment of osteoarthritis cartilage degeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 Figure 1 shows the effect of the change in shell flow rate on the morphology of core-shell microspheres in the present invention (core-shell ratio is 1:3, 1:5, 1:8), wherein Figure A is a morphology of core-shell microspheres under an optical microscope, Figure B is a diagram showing the effect of the change in shell flow rate on the shell diameter of core-shell microspheres, and Figure C is a diagram showing the effect of the change in shell flow rate on the particle size of core-shell microspheres.

[0016] Figure 2 Figure 1 shows the effect of the change in the core layer flow rate on the morphology of the core-shell microspheres in the present invention (core-shell ratios are 1:5, 3:5, and 5:5), wherein Figure A is a morphology of the core-shell microspheres under an optical microscope, Figure B is a diagram showing the effect of the change in the core layer flow rate on the shell diameter of the core-shell microspheres, and Figure C is a diagram showing the effect of the change in the core layer flow rate on the particle size of the core-shell microspheres.

[0017] Figure 3 Shown are the in vitro release behavior diagrams of rapamycin and KGN in the present invention, wherein Figure A is a release curve diagram of rapamycin in Rap@CSM microspheres, and Figure B is a release curve diagram of KGN in KGN@CSM microspheres; in the figure, Rap@CSM microspheres are core-shell microspheres (excluding second drug-loaded nanoparticles) prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap), and KGN@CSM microspheres are core-shell microspheres (excluding first drug-loaded nanoparticles) prepared using second drug-loaded nanoparticles (the drug loaded is KGN).

[0018] Figure 4 It shows the evaluation diagram of cartilage targeting performance, wherein Figure A is a confocal image and Figure B is a quantitative analysis of fluorescence intensity; in the figure, Dil is a cell membrane fluorescent probe, Lipo is the prepared liposome, Lipo-Pep is a liposome modified with the type II collagen targeting peptide WYRGRL, and Lipo-Pep+Dil is a liposome modified with the type II collagen targeting peptide WYRGRL labeled with Dil.

[0019] Figure 5 Shown are in vitro biocompatibility evaluation graphs of the core-shell microspheres of the present invention, wherein Figure A is a cell proliferation analysis graph after ATDC5 culture for 1, 3, and 5 days, and Figure B is a fluorescent image of cell staining after ATDC5 culture for 1, 3, and 5 days; in the figure, ATDC5 are mouse chondrocytes, Control is a pure culture medium, CSM are core-shell microspheres (without drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (without second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (without first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles.

[0020] Figure 6 Figures are shown as evaluation graphs of the apoptosis inhibition and reactive oxygen species scavenging performance of the drug-loaded core-shell microspheres of the present invention, wherein Figure A is a fluorescence image of ATDC5 stained with TUNEL, Figure B is a fluorescence image of ATDC5 stained with DCFH-DA, Figure C is a fluorescence quantitative analysis graph of apoptosis staining, and Figure D is a fluorescence quantitative analysis graph of ROS scavenging; in the figure, ATDC5 is mouse chondroblasts, TUNEL is terminal deoxynucleotidyl transferase-mediated dUTP in situ nick end labeling, DCFH-DA is 2',7'-dichlorofluorescein diacetate, R OS is reactive oxygen species, IL-1β is interleukin 1β, Control is pure culture medium, CSM is core-shell microspheres (without drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (without second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (without first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles.

[0021] Figure 7Shown are expression graphs of OA-related genes in ATDC5 cells of the present invention, wherein Graph A is an expression graph of COL2α1, Graph B is an expression graph of MMP9, Graph C is an expression graph of ADAMTS5, and Graph D is an expression graph of MMP13;

[0022] In the figure, ATDC5 is mouse chondrocytes, OA is osteoarthritis, COL2α1 is type II collagen α1, MMP9 is matrix metalloproteinase 9, ADAMTS5 is human metallopeptidase containing thrombospondin 5, MMP13 is matrix metalloproteinase 13, Control is pure culture medium, IL-1β is interleukin 1β, CSM is core-shell microspheres (without drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (without second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (without first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles.

[0023] Figure 8 Shown are the expression graphs of chondrogenesis-related genes in BMSCs cells of the present invention, wherein Figure A is the expression graph of Aggrecan, Figure B is the expression graph of COL2α1, and Figure C is the expression graph of SOX-9; in the figure, BMSCs are bone marrow mesenchymal stem cells, Aggrecan is proteoglycan, COL2α1 is type II collagen α1, SOX-9 is the transcription factor SOX-9, Control is a pure culture medium, CSM is a core-shell microsphere (without drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (without second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (without the first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles.

[0024] Fig. 9Shown are imaging evaluation graphs of the drug-loaded core-shell microspheres of the present invention after 8 weeks of treatment of OA, wherein Figure A is an X-ray image, Figure B is a two-dimensional image of Micro-CT scanning, Figure C is a statistical analysis graph of osteophyte volume, and Figure D is a statistical analysis graph of BMD; in the figure, BMD is bone density, Sham is a sham operation, PBS is a phosphate buffered saline, CSM is a core-shell microsphere (not containing drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (not containing second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (not containing first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles.

[0025] Fig.10 Shown are histological staining images of the drug-loaded core-shell microspheres of the present invention after 8 weeks of treatment of OA, wherein Figure A is a hematoxylin-eosin (H&E) staining image, and Figure B is a Safranin O / fast green staining image; in the figure, Sham is a sham operation, PBS is a phosphate buffered saline, CSM is a core-shell microsphere (not containing drug-loaded nanoparticles), Rap@CSM microspheres are core-shell microspheres prepared using first drug-loaded nanoparticles (the drug loaded is rapamycin Rap) (not containing second drug-loaded nanoparticles), KGN@CSM microspheres are core-shell microspheres prepared using second drug-loaded nanoparticles (the drug loaded is KGN) (not containing first drug-loaded nanoparticles), and Rap / KGN@CSM are core-shell microspheres containing first drug-loaded nanoparticles and second drug-loaded nanoparticles. DETAILED DESCRIPTION

[0026] The first aspect of the present invention provides a drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, which comprises a shell layer and a core layer from the outside to the inside, wherein the shell layer comprises a polymer matrix having photo-crosslinking properties and first drug-loaded nanoparticles loaded with a drug for regulating chondrocyte autophagy activity, and the core layer comprises a second drug-loaded nanoparticle containing a water-soluble polymer matrix, targeted cartilage matrix molecular modifications and loaded with a drug for promoting chondrogenesis, wherein the release rate of the drug for regulating chondrocyte autophagy activity is faster than the release rate of the drug for promoting chondrogenesis.

[0027] The drug-loaded core-shell microspheres with the above sequence regulating cell autophagy and chondrogenesis are also called drug-loaded core-shell microspheres with both regulating cell autophagy and chondrogenesis. The drug-loaded core-shell microspheres are prepared by microfluidics technology.

[0028] In the drug-loaded core-shell microspheres, in the shell layer, the first drug-loaded nanoparticles loaded with the drug for regulating the autophagy activity of chondrocytes are uniformly distributed in a polymer matrix with photo-crosslinking properties.

[0029] In the drug-loaded core-shell microspheres, in the core layer, the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with the drug promoting chondrogenesis are uniformly distributed in a water-soluble polymer matrix.

[0030] In the above-mentioned drug-loaded core-shell microspheres, in the shell layer, the polymer matrix containing photo-crosslinking properties is selected from at least one of methacrylated gelatin (GelMA), methacrylated hyaluronic acid (HAMA), methacrylated silk fibroin (SilMA), methacrylated chondroitin sulfate (ChSMA), methacrylated polylysine (PLMA), methacrylated polyarginine, and methacrylated polyglutamic acid.

[0031] The above polymer matrices all have good biocompatibility, and all have photoinduced cross-linking properties, and can be quickly cured to form hydrogels or microspheres by ultraviolet light or blue light irradiation. For example, the methacrylylated gelatin is a gelatin-derived protein material modified by methacrylic anhydride. Since it contains an arginine-glycine-aspartic acid (RGD) sequence, it has some properties similar to the natural cytoplasmic matrix and has good biocompatibility. The methacrylylated hyaluronic acid is given photocuring ability by introducing methacrylic groups into the hyaluronic acid molecular chain. The methacrylylated silk protein is methacrylylated to modify silk protein with glycidyl methacrylate, and double bonds are introduced into the silk protein molecules. The methacrylylated chondroitin sulfate is obtained by methacrylylating chondroitin sulfate. The methacrylylated polylysine is a double-bond modified polylysine, which can be cross-linked and cured into a gel under the action of a photoinitiator by ultraviolet and visible light. The methacrylated polyarginine is a double-bond modified polyarginine, which can be cross-linked and cured into a gel under the action of a photoinitiator by ultraviolet and visible light. The methacrylated polyglutamic acid is a double-bond modified polyglutamic acid, which can be cross-linked and cured into a gel under the action of a photoinitiator by ultraviolet and visible light.

[0032] In the drug-loaded core-shell microspheres, a photoinitiator is added to the polymer matrix having photo-crosslinking properties in the shell layer.

[0033] In the presence of a photoinitiator, a covalently cross-linked hydrogel can be rapidly formed by a photo-initiated free radical polymerization reaction under the irradiation of ultraviolet light or blue light (405 nm), so that the polymer matrix contains a photo-cross-linking property.

[0034] In a specific embodiment, the photoinitiator is phenyl (2,4,6-trimethylbenzoyl) phosphate lithium salt (CAS No. 85073-19-4).

[0035] In the above-mentioned drug-loaded core-shell microspheres, in the shell layer, the first drug-loaded nanoparticles are selected from at least one of mesoporous silica nanoparticles, mesoporous manganese dioxide nanoparticles, mesoporous polydopamine, metal organic frameworks, conjugated organic frameworks, and polylactic acid-glycolic acid copolymer nanoparticles.

[0036] The preparation process of the above-mentioned first drug-loaded nanoparticles is simple, the particle size is controllable, and it can be loaded with both hydrophobic drugs and hydrophilic drugs, and it has good biocompatibility and can be taken up by cells. For example, the preparation process of the mesoporous silica nanoparticles is simple, the particle size is controllable, and it can be loaded with both hydrophobic drugs and hydrophilic drugs, and it also has good biocompatibility. The mesoporous silica nanoparticles are silica nanoparticles with ordered and highly structured pores. The mesoporous manganese dioxide nanoparticles are manganese dioxide nanoparticles with ordered and highly structured pores. The mesoporous polydopamine is a dopamine polymer nanoparticle with a mesoporous structure. The metal organic framework (MOFs) is a coordination compound with a periodic structure formed by assembling organic ligands as linkers and metal ions or clusters as nodes through coordination bonds, such as MOF-5, MOF-118, MOF-177, MOF-74, HKUST-1, ZIF-8, MIL-100 (Fe), MIL-101 (Fe), and MIL-53 (Fe). The conjugated organic framework (COF) is formed by connecting organic monomers with specific structures through covalent bonds, and is a polymer material with a periodic pore structure, such as COF-5, COF-316, COF-300, COF-366, and COF-TpPa-1. The polylactic acid-glycolic acid copolymer nanoparticles (PLGA) are copolymers formed by connecting lactic acid and glycolic acid monomers through ester bonds.

[0037] In the above-mentioned drug-loaded core-shell microspheres, in the shell layer, the drug that regulates chondrocyte autophagy activity is selected from at least one of rapamycin, pravastatin, metformin, α-ketoglutaric acid, and artemisinin.

[0038] The above drugs can inhibit chondrocyte inflammatory response, regulate autophagy activity and inhibit cell apoptosis, protect the normal physiological function of chondrocytes, and play a therapeutic effect in the treatment of osteoarthritis. For example, the rapamycin is an autophagy activator, which can inhibit mTORC1 and upregulate the expression of cell autophagy level to slow down the progression of OA.

[0039] In the above-mentioned drug-loaded core-shell microspheres, in the shell layer, the weight ratio of the polymer matrix with photocrosslinking properties to the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity is 10-200:1-100, specifically 10-100:1-100, 100-200:1-100, 10-200:1-50, 10-200:50-100.

[0040] In a specific embodiment, the weight ratio of the photoinitiator to the photocrosslinking polymer matrix is ​​1-10:10-200, such as 1-10:10-100, 1-10:100-200, 1-5:10-200, 5-10:10-200.

[0041] In a specific embodiment, the weight ratio of the first drug-loaded nanoparticles to the loaded drug for regulating chondrocyte autophagy activity is 100:1-50, such as 100:1-20, 100:20-40, 100:40-50.

[0042] In the above-mentioned drug-loaded core-shell microspheres, in the core layer, the water-soluble polymer matrix is ​​selected from at least one of methylcellulose (CAS No. 9004-67-5), carboxymethyl chitosan (CAS No. 83512-85-0), sodium alginate (CAS No. 9005-38-3), and hyaluronic acid (CAS No. 9004-61-9).

[0043] The above water-soluble polymer matrices have good water solubility and good biocompatibility.

[0044] In the above-mentioned drug-loaded core-shell microspheres, in the core layer, the second drug-loaded nanoparticles are modified with targeted cartilage matrix molecules.

[0045] In the above-mentioned drug-loaded core-shell microspheres, in the core layer, the targeted cartilage matrix molecule modified by the second drug-loaded nanoparticles is selected from at least one of type II collagen targeting peptides and cationic polypeptides.

[0046] In a specific embodiment, the type II collagen targeting peptide is WYRGRL (amino acid sequence: tryptophan-tyrosine-arginine-glycine-arginine-leucine). The type II collagen targeting peptide is grafted onto distearoylphosphatidylethanolamine-polyethylene glycol.

[0047] WYRGRL is a type II collagen targeting peptide that has an inherent affinity for the cartilage matrix component of collagen II and can be used for cartilage-targeted drug delivery; by specifically binding to type II collagen, the retention time of the drug in cartilage tissue is increased. When used specifically, distearoylphosphatidylethanolamine-polyethylene glycol-type II collagen targeting peptide (DSPE-PEG-WYRGRL) is required. WYRGRL is grafted on DSPE-PEG for modification of the second drug-loaded nanoparticles. By modifying the surface of the second drug-loaded nanoparticles with type II collagen targeting peptides, the retention time of the drug KGN in cartilage tissue is increased, which protects chondrocytes on the one hand and promotes the differentiation of bone marrow mesenchymal stem cells into chondrocytes on the other hand, thereby repairing damaged cartilage.

[0048] In a specific embodiment, the cationic polypeptide is selected from at least one of poly-lysine (CAS No. 25988-63-0) and poly-arginine (CAS No. 26982-20-7).

[0049] The cationic polypeptide is a type of polypeptide molecule with positive charge characteristics (such as poly-lysine and poly-arginine), which can interact with molecules in cartilage (such as hyaluronic acid and chondroitin sulfate) through its charge characteristics to play a targeting role, thereby improving the targeting and action time of the drug.

[0050] In a specific embodiment, the weight ratio of the second drug-loaded nanoparticles to the modified targeted cartilage matrix molecules is 100:1-20, such as 100:1-10, 100:10-15, 100:15-20.

[0051] In the above-mentioned drug-loaded core-shell microspheres, in the core layer, the second drug-loaded nanoparticles are selected from at least one of liposomes, polymer vesicles, and exosomes.

[0052] The above-mentioned second drug-loaded nanoparticles can be loaded with both hydrophobic drugs and hydrophilic drugs, and are easily taken up by cells. For example, the liposomes are hollow particles assembled from cholesterol, lecithin and their derivatives. Polymer vesicles are vesicle structures composed of amphiphilic block copolymers, which are composed of natural synthetic surfactants and phospholipids that cannot simply associate into micelles. Exosomes are tiny vesicles that cells actively secrete outside the cells through exocytosis, including those derived from bone marrow mesenchymal stem cells, synovial mesenchymal stem cells, and adipose mesenchymal stem cells.

[0053] In the drug-loaded core-shell microspheres, in the core layer, the cartilage-promoting drug is selected from at least one of KGN (Kartogenin), chondroitin sulfate, transforming growth factor-β, and icariin (CAS No. 489-32-7).

[0054] The above-mentioned drugs can effectively promote the differentiation of mesenchymal stem cells into chondrocytes, achieve the repair of articular cartilage damage, and show certain therapeutic effects in OA animal models. For example, the KGN is a small heterocyclic drug compound that can effectively promote the differentiation of mesenchymal stem cells into chondrocytes by activating the CBFβ-RUNX1 signaling pathway, achieve the repair and regeneration of articular cartilage, and show good therapeutic effects in a variety of OA animal models. The chondroitin sulfate (CS) is a type of glycosaminoglycan that is covalently linked to proteins to form proteoglycans. The transforming growth factor-β (TGF-β) belongs to a group of newly discovered TGF-β superfamily that regulates cell growth and differentiation.

[0055] In a specific embodiment, the weight ratio of the second drug-loaded nanoparticles to the loaded chondrogenesis-promoting drug is 100:1-20, such as 100:1-10, 100:10-15, 100:15-20.

[0056] In the above-mentioned drug-loaded core-shell microspheres, in the core layer, the weight ratio of the water-soluble polymer matrix to the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with chondrogenesis-promoting drugs is 10-150:1-100, specifically 10-100:1-100, 100-150:1-100, 100-150:1-100, 10-150:1-50, 10-150:50-100.

[0057] The second aspect of the present invention provides a method for preparing drug-loaded core-shell microspheres for sequence regulation of cell autophagy and chondrogenesis, comprising the following steps:

[0058] 1) loading a drug that regulates chondrocyte autophagy activity into a first drug-loaded nanoparticle, and uniformly mixing the obtained first drug-loaded nanoparticle loaded with the drug that regulates chondrocyte autophagy activity with a polymer matrix having photo-crosslinking properties in a solvent to obtain a shell layer solution; and / or, modifying a second drug-loaded nanoparticle with targeted cartilage matrix molecules, and loading a chondrogenesis drug into the second drug-loaded nanoparticle, and uniformly mixing the obtained second drug-loaded nanoparticle modified with targeted cartilage matrix molecules and loaded with a chondrogenesis-promoting drug with a water-soluble polymer matrix in a solvent to obtain a core layer solution;

[0059] 2) using a microfluidic chip, respectively passing a shell layer solution and a core layer solution into different flow channels to form a shell layer channel and a core layer channel, then mixing the shell layer solution in the shell layer channel with the core layer solution in the core layer channel to form a core-shell solution located in a continuous phase channel, and passing an oily substance into the continuous phase channel to form a double-layer structure microsphere having a shell layer and a core layer in sequence from the outside to the inside of the core-shell solution, so that the release rate of the drug regulating the autophagy activity of chondrocytes in the shell layer solution is faster than the release rate of the drug promoting chondrogenesis in the core layer solution;

[0060] 3) The double-layer structure microspheres are irradiated with a blue light source for photocuring to provide drug-loaded core-shell microspheres.

[0061] In the above preparation method, in step 1), the drug that regulates chondrocyte autophagy activity is loaded in the first drug-loaded nanoparticles, including: dissolving the first drug-loaded nanoparticles and the drug that regulates chondrocyte autophagy activity in a first solvent and stirring, centrifuging to collect the drug-loaded nanoparticles, then washing with a second solvent, and centrifuging again to obtain the first drug-loaded nanoparticles loaded with the required drug that regulates chondrocyte autophagy activity.

[0062] In a specific embodiment, the first drug-loaded nanoparticles are selected from at least one of mesoporous silica nanoparticles, mesoporous manganese dioxide nanoparticles, mesoporous polydopamine, metal organic frameworks, conjugated organic frameworks, and polylactic acid-glycolic acid copolymer nanoparticles.

[0063] In a specific embodiment, the drug for regulating chondrocyte autophagy activity is selected from at least one of rapamycin, pravastatin, metformin, α-ketoglutaric acid, and artemisinin.

[0064] In a specific embodiment, the weight ratio of the first drug-loaded nanoparticles to the drug for regulating chondrocyte autophagy activity is 100:1-50, such as 100:1-20, 100:20-40, 100:40-50.

[0065] In a specific embodiment, the first solvent is selected from at least one of anhydrous ethanol, water or phosphate buffer.

[0066] In a specific embodiment, the ratio of the added weight mg of the first drug-loaded nanoparticles to the added volume mL of the first solvent is 5-20:1-5, specifically 5-10:1-5, 10-20:1-5, 5-20:1-2, 5-20:2-5.

[0067] In a specific embodiment, the stirring is performed at room temperature in the dark.

[0068] In a specific embodiment, the stirring is for 6-48 hours, preferably 24 hours.

[0069] In a specific embodiment, the second solvent is selected from at least one of 5-15% (v / v) ethanol aqueous solution, water or phosphate buffer.

[0070] In one specific embodiment, the second solvent is a 10% (v / v) ethanol aqueous solution.

[0071] In one embodiment, the washing is performed 1-3 times to remove unloaded drugs.

[0072] In a specific embodiment, the centrifugation conditions are: the centrifugal speed is 2000-10000 rpm, and the centrifugal time is 3-20 minutes.

[0073] In the above preparation method, in step 1), the concentration of the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity is 0.1-100 mg / mL, preferably 25 mg / mL.

[0074] In the above preparation method, in step 1), the concentration of the polymer matrix containing photo-crosslinking properties is 1-200 mg / mL, preferably 120 mg / mL.

[0075] In the above preparation method, in step 1), the weight ratio of the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity to the polymer matrix containing photo-crosslinking properties is 0.1-100:1-200, specifically 0.1-25:1-200, 25-100:1-200, 0.1-100:1-120, 0.1-100:120-200, preferably 25:120.

[0076] In the above preparation method, in step 1), the targeted cartilage matrix molecule is selected from at least one of type II collagen targeting peptide and cationic polypeptide.

[0077] In a specific embodiment, the type II collagen targeting peptide is WYRGRL (amino acid sequence: tryptophan-tyrosine-arginine-glycine-arginine-leucine). The type II collagen targeting peptide is grafted onto distearoylphosphatidylethanolamine-polyethylene glycol.

[0078] The type II collagen targeting peptide is to be modified on the second drug-carrying nanoparticles such as liposomes, and distearoylphosphatidylethanolamine-polyethylene glycol-type II collagen targeting peptide (DSPE-PEG-WYRGRL) is required to allow WYRGRL to be grafted onto DSPE-PEG.

[0079] In a specific embodiment, the cationic polypeptide is selected from at least one of poly-lysine (CAS No. 25988-63-0) and poly-arginine (CAS No. 26982-20-7). The cationic polypeptide is grafted onto distearoylphosphatidylethanolamine-polyethylene glycol.

[0080] In the above preparation method, in step 1), the second drug-loaded nanoparticles are selected from at least one of liposomes, polymer vesicles, and exosomes.

[0081] In one specific embodiment, the second drug-loaded nanoparticles are liposomes.

[0082] In a preferred embodiment, the liposomes include lecithin, cholesterol and octadecylamine, and the weight ratio of the lecithin, cholesterol and octadecylamine is 400:3-5:35-45, specifically 400:3-4:35-45, 400:4-5:35-45, 400:3-5:35-40, 400:3-5:40-45, preferably 400:4:40.

[0083] In a preferred embodiment, the liposome preparation process is to dissolve 0.4g of lecithin, 4mg of octadecylamine and 40mg of cholesterol in 5mL of anhydrous ethanol solution; after complete dissolution, transfer it to a rotary evaporation flask and rotary evaporate it at 35°C to prepare a blank group lipid film; then, add 10mL of phosphate buffer to the film, rehydrate it to obtain a liposome suspension, stir the liposome suspension for 30 minutes, and use an ultrasonic instrument to obtain a uniform liposome suspension; finally, use a 0.22μm polycarbonate filter membrane to filter the solution multiple times to obtain blank liposomes with uniform particle size.

[0084] In the above preparation method, in step 1), the cartilage-promoting drug is selected from at least one of KGN (Kartogenin), chondroitin sulfate, transforming growth factor-β, and icariin (CAS No. 489-32-7).

[0085] In the above preparation method, in step 1), the second drug-loaded nanoparticles are modified with targeted cartilage matrix molecules, and the chondrogenesis drug is loaded into the second drug-loaded nanoparticles, including: dissolving the targeted cartilage matrix molecules, the chondrogenesis drug and the second drug-loaded nanoparticles in a third solvent, followed by rotary evaporation and resuspending to obtain the desired second drug-loaded nanoparticles modified with targeted cartilage matrix molecules and loaded with the chondrogenesis-promoting drug.

[0086] In a specific embodiment, the weight ratio of the targeted cartilage matrix molecules to the second drug-loaded nanoparticles is 30-50:300-500, such as 30-40:300-500, 40-50:300-500, 30-50:300-444, 30-50:444-500, preferably 40:444.

[0087] In a specific embodiment, the weight ratio of the chondrogenic drug to the second drug-loaded nanoparticles is 5-20:300-500, such as 5-10:300-500, 10-20:300-500, 5-20:300-444, 5-20:444-500, preferably 10:444.

[0088] In a specific embodiment, the third solvent is selected from at least one of anhydrous ethanol, water or phosphate buffer.

[0089] In a specific embodiment, the ratio of the volume mL of the third solvent to the weight mg of the second drug-loaded nanoparticles is 1-20:300-500, such as 1-5:300-500, 5-20:300-500, 1-20:300-444, 1-20:444-500, preferably 5:444.

[0090] In a specific embodiment, the rotary evaporation temperature is 30-50° C., preferably 35° C., and the rotary evaporation time is 10-30 minutes, preferably 20 minutes. The rotary evaporation prepares the lipid film.

[0091] In a specific embodiment, the resuspending comprises adding a fourth solvent to obtain a lipid film by rotary evaporation for hydration, and stirring, ultrasonicating, and filtering the obtained liposome suspension.

[0092] In a preferred embodiment, the fourth solvent is selected from at least one of water and phosphate buffer.

[0093] The phosphate buffer is PBS buffer. Specifically, the main components of the phosphate buffer are Na2HPO4, KH2PO 4 , NaCl and KCl.

[0094] In a preferred embodiment, the ratio of the volume mL of the fourth solvent to the weight mg of the second drug-loaded nanoparticles is 5-20:300-500, specifically 5-10:300-500, 10-20:300-500, 5-20:300-444, 5-20:444-500, preferably 10:444.

[0095] In a preferred embodiment, the stirring time is 25-35 min, preferably 30 min.

[0096] In a preferred embodiment, the ultrasonic time is 5-20 min, preferably 10 min.

[0097] In a preferred embodiment, the filtration is performed using a membrane filter, and the membrane filter is a 0.22 μm polycarbonate membrane.

[0098] In the above preparation method, in step 1), the concentration of the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with the chondrogenesis-promoting drug is 0.1-100 mg / mL, preferably 25 mg / mL.

[0099] In the above preparation method, in step 1), the concentration of the water-soluble polymer matrix is ​​1 to 150 mg / mL, preferably 20 mg / mL.

[0100] In the above preparation method, in step 1), the weight ratio of the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with chondrogenesis-promoting drugs to the water-soluble polymer matrix is ​​0.1-100:1-150, specifically 0.1-25:1-150, 25-100:1-150, 0.1-100:1-20, 0.1-100:20-150, preferably 25:20.

[0101] In the above preparation method, in step 1), the solvent is water or phosphate buffer.

[0102] In one embodiment, the water is ultrapure water.

[0103] In a specific embodiment, the phosphate buffer is a PBS buffer (pH=7.2-7.5, preferably 7.4). Specifically, the main components of the phosphate buffer are Na2HPO4, KH2PO 4 , NaCl and KCl.

[0104] In the above preparation method, in step 1), the amount of solvent added to the shell solution is 1-10 mL.

[0105] In the above preparation method, in step 1), the amount of solvent added to the core layer solution is 1-10 mL.

[0106] In the above preparation method, in step 1), the uniform mixing can be achieved by continuous stirring, and the stirring conditions are: rotation speed is 10-500 rpm, preferably 50-200 rpm; stirring time is 0.5-24 hours, preferably 1-12 hours; temperature is 15-45°C, preferably 20-40°C.

[0107] In the above preparation method, in step 2), the measurement conditions of the microfluidic chip are: the core layer water phase flow rate is 0.1 to 50 μL / min, for example, 0.1 to 1 μL / min, 1 to 3 μL / min, 3 to 5 μL / min, 5 to 50 μL / min, 10 to 40 μL / min, specifically, the core layer flow rate can be 1 μL / min, 3 μL / min, 5 μL / min; the shell layer water phase flow rate is 0.1 to 100 μL / min, for example, 0.1 to 3 μL / min n, 3-5μL / min, 5-8μL / min, 8-100μL / min, specifically, the shell flow rate can be 3μL / min, 5μL / min, 8μL / min; the oil phase flow rate is 1-200μL / min, for example 1-10μL / min, 10-20μL / min, 20-30μL / min, 30-200μL / min, specifically, the oil phase flow rate can be 10μL / min, 20μL / min, 30μL / min.

[0108] The above-mentioned microfluidic chip technology is to integrate the basic operation units such as sample preparation, reaction, separation, and detection of biological, chemical, and medical analysis processes into a micrometer-scale chip to automatically complete the entire analysis process. This technology can load the shell solution and the core layer solution into a syringe respectively, and pass different flow channels through the syringe pump to form a shell channel and a core layer channel respectively, and then mix the shell solution in the shell channel with the core layer solution in the core layer channel to form a core-shell solution located in the continuous phase channel. After the oily substance is passed into the continuous phase channel, the core-shell solution is formed into a double-layer structure microsphere with a shell layer and a core layer arranged from the outside to the inside. At the same time, the oily substance can be loaded into the syringe and flow into the continuous phase channel through the syringe pump. The flow rate of the core layer and shell layer solutions is controlled by the syringe pump respectively to obtain microspheres with different core layer thicknesses, different shell layer thicknesses, and different particle sizes.

[0109] In the above preparation method, in step 2), the oily substance is mineral oil containing Span 80.

[0110] In one specific embodiment, the mineral oil is a commonly used mineral oil.

[0111] In one embodiment, the Span 80 is a non-ionic surfactant.

[0112] In a specific embodiment, the concentration of Span80 in mineral oil is 1-100 mg / mL, preferably 20 mg / mL.

[0113] In the above preparation method, in step 3), the wavelength of the blue light source is 400-410nm, preferably 405nm.

[0114] The blue light source is used to perform photocuring on the drug-loaded core-shell microspheres.

[0115] In the above preparation method, in step 3), the time of the photocuring treatment is 10-60s, preferably 20s.

[0116] In the above preparation method, in step 3), the light curing treatment is followed by washing and centrifugation to obtain a precipitate to obtain drug-loaded core-shell microspheres.

[0117] In a specific embodiment, the washing times are 1-5 times, preferably 3 times.

[0118] In a specific embodiment, the washing reagent is PBS buffer (pH=7.2-7.5, preferably 7.4).

[0119] In a specific embodiment, the centrifugal conditions are: a centrifugal speed of 500-2000 rpm and a centrifugal time of 2-10 minutes for removing mineral oil.

[0120] In the above preparation method, in step 3), the particle size of the drug-loaded core-shell microspheres is 10 to 500 μm.

[0121] In the above preparation method, in step 3), the core layer thickness of the drug-loaded core-shell microspheres is 5 to 200 μm.

[0122] In the above preparation method, in step 3), the shell thickness of the drug-loaded core-shell microspheres is 5 to 300 μm.

[0123] The drug-loaded core-shell microspheres need to have a suitable particle size to facilitate injection into the joint cavity. Larger-sized drug-loaded core-shell microspheres are prone to injection blockage, while smaller-sized drug-loaded core-shell microspheres are difficult to obtain a suitable drug loading amount.

[0124] In the drug-loaded core-shell microspheres, the release rate of the shell drug is faster than the release rate of the core drug. The two drugs are loaded in different nanoparticles, and then suspended in different polymer matrices, and loaded in different channels of microfluidics, so that the drug-loaded nanoparticles are anchored in the shell and core layers of the microspheres respectively. Due to the difference in the spatial distribution of the shell drug and the core drug, when the drug in the drug-loaded core-shell microspheres is released into the external environment, the release rate of the shell drug is faster than the release rate of the core drug.

[0125] The polymers involved in the drug-loaded core-shell microspheres are all water-soluble polymers, which are difficult to load and deliver for poorly water-soluble drug molecules (such as Rap and KGN). Further, the drug molecules with poor water solubility are loaded with nanoparticles, and then anchored in the different layers of the core-shell structure. Due to the different distribution of drugs in the shell layer and the core layer, there are differences in the release of drugs, and the release of shell drugs is faster than the release of core drugs. In addition, according to the microenvironment characteristics of osteoarthritis, it is necessary to intervene in microenvironment regulation (including reducing inflammation and restoring autophagic activity) first, and then promote cartilage formation, in order to achieve the best osteoarthritis treatment effect. In order to achieve the effect of this sequence regulating cell autophagy and cartilage formation, this core-shell structure and drug distribution are created by the present application to meet the above needs. On the whole, the drug-loaded core-shell microspheres have the uniqueness for the treatment of osteoarthritis.

[0126] The third aspect of the present invention provides a drug-loaded core-shell microsphere for sequence regulation of cell autophagy and chondrogenesis, which is prepared by the above method.

[0127] The fourth aspect of the present invention provides the use of the drug-loaded core-shell microspheres with the above sequence regulating cell autophagy and chondrogenesis in the preparation of drugs for treating osteoarthritis cartilage degeneration diseases.

[0128] In the above application, the osteoarthritis cartilage degeneration disease is a chronic joint disease characterized by degenerative lesions of articular cartilage and secondary bone hyperplasia.

[0129] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention.

[0130] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0131] It should be noted that the process equipment or devices not specifically specified in the following embodiments are all conventional equipment or devices in the art; all pressure values ​​and ranges refer to relative pressures.

[0132] In addition, it should be understood that one or more method steps mentioned in the present invention do not exclude the existence of other method steps before or after the combination step or the insertion of other method steps between these explicitly mentioned steps, unless otherwise specified; it should also be understood that the combination connection relationship between one or more devices / apparatuses mentioned in the present invention does not exclude the existence of other devices / apparatuses before or after the combination device / apparatus or the insertion of other devices / apparatuses between these explicitly mentioned two devices / apparatuses, unless otherwise specified. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or the scope of the present invention. Changes or adjustments in their relative relationships should also be regarded as the scope of the present invention without substantially changing the technical content.

[0133] Example 1

[0134] (1) Preparation of the first drug-loaded nanoparticles loaded with rapamycin: 20 mg of degradable mesoporous silica nanoparticles (bMSN) and 5 mg of rapamycin (Rap) were dispersed in 2 mL of anhydrous ethanol and stirred at room temperature for 24 hours under light-proof conditions. Then, the mixture was washed with a 10% (v / v) ethanol aqueous solution and centrifuged to collect the drug-loaded nanoparticles Rap@bMSN.

[0135] (2) Preparation of the second drug-loaded nanoparticles modified with targeted cartilage matrix molecules and loaded with chondrogenic drugs: 10 mg KGN and 40 mg distearoylphosphatidylethanolamine-polyethylene glycol-type II collagen targeting peptide (DSPE-PEG-WYRGRL) were dissolved in 5 mL of anhydrous ethanol solution together with 400 mg lecithin, 4 mg octadecylamine and 40 mg cholesterol. After complete dissolution, they were transferred to a rotary evaporation flask and rotary evaporated at 35°C to prepare a lipid film. Subsequently, 10 mL of PBS buffer (pH 7.4) was added to the lipid film to rehydrate it to obtain a liposome suspension. The liposome suspension was stirred for 30 minutes and treated with an ultrasonic instrument to obtain a uniform liposome suspension. Finally, the solution was filtered multiple times using a 0.22 μm polycarbonate filter membrane to prepare KGN-loaded liposomes KGN@Lipo and type II collagen targeting peptide-modified drug-loaded liposomes KGN@Lipo-Pep.

[0136] (3) A conventional synthesis method was used to synthesize a polymer matrix with photo-crosslinking properties: methacryloyl gelatin. That is, 10 g of gelatin was added to 100 mL of deionized water, and the solution was stirred continuously in a water bath at a constant temperature of 50°C until the gelatin was completely dissolved. Under complete light-shielding conditions, methacrylic anhydride was added to the gelatin solution at a rate of 1 mL / min, and stirred continuously at 50°C for 3 hours. Subsequently, the prepared solution was placed in a dialysis bag with a molecular weight of 14 kDa and dialyzed in deionized water at a temperature of 50°C for 1 week to remove impurities in the prepared solution, and the deionized water was replaced every 4 hours. Finally, the prepared methacryloyl gelatin (GelMA) was freeze-dried to obtain a dry sample.

[0137] (4) Preparation of drug-loaded core-shell microspheres: 120 mg / mL GelMA, 5 mg / mL phenyl (2,4,6-trimethylbenzyl) phosphite (LAP) as a photoinitiator, and 25 mg / mL Rap@bMSN were mixed in 5 mL of water at 30 °C and 100 rpm for 12 h and mixed to obtain a shell solution.

[0138] 20 mg / mL methylcellulose and 25 mg / mL KGN@Lipo-Pep were stirred continuously in 5 mL water at 30°C and 100 rpm for 12 hours and mixed evenly to obtain a core layer solution.

[0139] Using a microfluidic chip, the shell layer solution and the core layer solution were loaded into syringes respectively, and flowed into different flow channels through a syringe pump to form a shell layer channel and a core layer channel, wherein the shell layer solution flowed in at an aqueous phase flow rate of 3 μL / min, and the core layer solution flowed in at an aqueous phase flow rate of 1 μL / min. The shell layer solution in the shell layer channel was mixed with the core layer solution in the core layer channel to form a core-shell solution located in the continuous phase channel. After mineral oil containing 20 mg / mL Span80 was passed into the continuous phase channel, the core-shell solution formed a double-layer structure microsphere with a shell layer and a core layer sequentially provided from the outside to the inside.

[0140] The double-layer structured microspheres were irradiated with a 405 nm blue light source for 20 s, the drug-loaded core-shell microspheres were photocured, and the obtained hydrogel microspheres were transferred to a PBS solution (pH = 7.4) and washed three times. The resulting hydrogel microspheres were then collected by centrifugation and the mineral oil was removed to obtain the dual-drug-loaded core-shell microspheres Rap / KGN@CSM.

[0141] (5) Using the same steps as step (4), pure core-shell microspheres (CSM), single drug-loaded core-shell microspheres (Rap@CSM and KGN@CSM) and unloaded core-shell microspheres (bMSN@CSM) were prepared. At the same time, the flow rates of the core layer solution (flow rates of 1, 3, and 5 μL / min, respectively) and the shell layer solution (flow rates of 3, 5, and 8 μL / min, respectively) were controlled by injection pumps to obtain microspheres with different core / shell thicknesses and different particle sizes. The morphology and double-layer structure of the microspheres were observed under a microscope, and the ImageJ software was used to analyze the thickness of the core / shell layer and the particle size of the microspheres at different flow rates. The specific results are shown in Figure 1 , 2 .

[0142] Depend on Figure 1 The effect of shell flow rate change on the morphology of core-shell microspheres can be seen by fixing the mobile phase at 30 μL / min, changing the shell flow rate, and analyzing the effect of different flow rates on the core / shell thickness and CSM microsphere particle size. Figure 1 As shown in A, the core layer flow rate is fixed at 1 μL / min, and the shell layer flow rate is changed to 3, 5, and 8 μL / min. ImageJ is used to analyze the particle size of the microsphere shell layer. The change of the shell layer flow rate can obtain uniform spherical CSM microspheres with obvious core-shell structure. As the flow rate of the shell layer channel increases, the diameter of the CSM microsphere shell will increase accordingly, and the corresponding CSM microsphere particle size will also increase accordingly ( Figure 1 B and Figure 1 C).

[0143] Depend on Figure 2 The effect of changing the flow rate of the core layer on the morphology of core-shell microspheres shows that the oil phase velocity is fixed at 30 μL / min, the flow rate of the core layer is changed, and the effect of different flow rates on the thickness of the core / shell layer and the particle size of the CSM microspheres is analyzed. Figure 2 As shown in Figure A, the shell layer flow rate is fixed at 5 μL / min, and the core layer flow rate is changed to 1, 3, and 5 μL / min, respectively, to obtain uniform spherical CSM microspheres with obvious core-shell structure. As the core layer channel flow rate increases, the diameter of the CSM microsphere core layer will increase accordingly, and the corresponding CSM microsphere particle size will also increase accordingly ( Figure 2 B and Figure 2 C).

[0144] Example 2

[0145] (1) Preparation of the first drug-loaded nanoparticles loaded with artemisinin: 20 mg of mesoporous polydopamine nanoparticles and 5 mg of artemisinin were dispersed in 2 mL of anhydrous ethanol and stirred at room temperature for 24 hours under light-proof conditions. Then, the mixture was washed with a 10% (v / v) ethanol aqueous solution and centrifuged to collect the drug-loaded nanoparticles Art@MPDA.

[0146] (2) Preparation of the second drug-loaded nanoparticles for targeted cartilage matrix molecular modification and loading of chondrogenic drugs: 10 mg of icariin and 40 mg of distearoylphosphatidylethanolamine-polyethylene glycol-polylysine (DSPE-PEG-PLL) were dissolved in 5 mL of anhydrous ethanol solution together with 400 mg of lecithin, 4 mg of octadecylamine and 40 mg of cholesterol. After complete dissolution, they were transferred to a rotary evaporation flask and rotary evaporated at 35°C to prepare a lipid film. Subsequently, 10 mL of PBS buffer (pH 7.4) was added to the lipid film to rehydrate it to obtain a liposome suspension. The liposome suspension was stirred for 30 minutes and treated with an ultrasonic instrument to obtain a uniform liposome suspension. Finally, the solution was filtered multiple times using a 0.22 μm polycarbonate filter membrane to prepare icariin-loaded liposomes ICA@Lipo and cationic peptide-modified drug-loaded liposomes ICA@Lipo-Pep.

[0147] (3) A conventional synthesis method was used to synthesize a polymer matrix with photo-crosslinking properties: methacryloyl gelatin. That is, 10 g of gelatin was added to 100 mL of deionized water, and the solution was stirred continuously in a water bath at a constant temperature of 50°C until the gelatin was completely dissolved. Under complete light-shielding conditions, methacrylic anhydride was added to the gelatin solution at a rate of 1 mL / min, and stirred continuously at 50°C for 3 hours. Subsequently, the prepared solution was placed in a dialysis bag with a molecular weight of 14 kDa and dialyzed in deionized water at a temperature of 50°C for 1 week to remove impurities in the prepared solution, and the deionized water was replaced every 4 hours. Finally, the prepared methacryloyl gelatin (GelMA) was freeze-dried to obtain a dry sample.

[0148] (4) Preparation of drug-loaded core-shell microspheres: 120 mg / mL methacryloyl gelatin, 5 mg / mL phenyl (2,4,6-trimethylbenzyl) phosphite (LAP) as a photoinitiator, and 25 mg / mL Art@MPDA were mixed in 5 mL of water at 30 °C and 100 rpm for 12 h and mixed to obtain a shell solution.

[0149] 20 mg / mL carboxymethyl chitosan and 25 mg / mL ICA@Lipo-Pep were stirred continuously in 5 mL water at 30°C and 100 rpm for 12 h and mixed evenly to obtain a core layer solution.

[0150] Using a microfluidic chip, the shell layer solution and the core layer solution were loaded into syringes respectively, and flowed into different flow channels through a syringe pump to form a shell layer channel and a core layer channel, wherein the shell layer solution flowed in at an aqueous phase flow rate of 3 μL / min, and the core layer solution flowed in at an aqueous phase flow rate of 1 μL / min. The shell layer solution in the shell layer channel was mixed with the core layer solution in the core layer channel to form a core-shell solution located in the continuous phase channel. After mineral oil containing 20 mg / mL Span80 was passed into the continuous phase channel, the core-shell solution formed a double-layer structure microsphere with a shell layer and a core layer sequentially provided from the outside to the inside.

[0151] The double-layer structured microspheres were irradiated with a 405 nm blue light source for 20 s, the drug-loaded core-shell microspheres were photocured, and the obtained hydrogel microspheres were transferred to a PBS solution (pH = 7.4) and washed three times. The microspheres were then collected by centrifugation and the mineral oil was removed to obtain dual-drug-loaded core-shell microspheres (Art / ICA@CSM).

[0152] Example 3 In vitro drug release assay

[0153] 30 mg of Rap@CSM and 30 mg of KGN@CSM microspheres obtained in Example 1 were dispersed in 1 mL of PBS (pH = 7.4), respectively, and the dispersion was placed in a dialysis bag, then immersed in a centrifuge tube containing 5 mL of PBS solution (pH = 7.4), and finally placed in a shaker for shaking incubation (37°C, 80 rpm). After the predetermined time is reached, 1 mL of the solution is drawn and then supplemented with the same volume of fresh PBS. Finally, a standard curve of Rap was established at 278 nm using an ultraviolet spectrophotometer, and a standard curve of KGN was established at 280 nm. The drug concentrations of Rap and KGN in the solution were then detected by an ultraviolet spectrophotometer, and the release kinetics of Rap and KGN were analyzed. The specific results are shown in Figure 3 .

[0154] Depend on Figure 3 The in vitro release behavior of rapamycin and KGN showed that Figure 3 A shows that Rap in Rap@CSM microspheres showed a fast release, and the cumulative release amount reached 91.41±1.27% on the 19th day. Figure 3 B shows that the release of KGN from KGN@CSM microspheres is relatively slow, and the cumulative release of KGN on the 19th day is 56.72±0.64%.

[0155] Example 4 Cartilage Targeting Performance Evaluation

[0156] ATDC5 cells were cultured at 1×10 5The cells were inoculated into confocal dishes at a density of 100 cells per well and co-cultured with blank liposomes (Lipo+Dil) and peptide-modified liposomes (Lipo-Pep+Dil) stained with cell membrane fluorescent probe Dil for 24 hours. The confocal microscope was used to take pictures. The specific results are shown in Figure 4 .

[0157] Blank liposomes and peptide-modified liposomes were stained with cell membrane fluorescent probe Dil, and then co-cultured with chondrocytes to evaluate the cartilage targeting properties of Lipo-Pep ( Figure 4 ). As can be seen from the fluorescence images, a large number of fluorescent particles gathered around the cell nuclei in the Lipo-Pep group, which was significantly more than that in the Lipo group ( Figure 4 A). The fluorescence quantitative result of the Lipo group was 21.0±0.8, while the fluorescence intensity of the Lipo-Pep group was 51.1±2.5 ( Figure 4 B). The results of fluorescence quantification show that chondrocytes phagocytize more Lipo-Pep than Lipo, indicating that the peptide WYRGRL modification can improve the ability to target the cartilage matrix.

[0158] Example 5 In vitro biocompatibility of core-shell microspheres

[0159] (1) CCK-8 detection: After the cells were co-cultured with the hydrogel microspheres for 1, 3, and 5 days, they were washed three times with PBS. CCK-8 and serum-free culture medium were mixed in a ratio of 1:9 to prepare a working solution, and then the serum-free culture medium containing CCK-8 working solution was added to the well plate. 200 μL of CCK-8 working solution was added to each well, and the well plate was protected from light during the entire process of adding. Then, the well plate with the working solution was placed in a 37°C incubator and incubated for 30 minutes. Finally, the well plate was removed from the incubator, 100 μL was aspirated into each well of a 96-well plate, and the OD value at a wavelength of 450 nm was detected using a multifunctional microplate reader. The specific results are shown in Figure 5 .

[0160] (2) Live / dead cell staining: Wash the cells three times with PBS, and prepare Calcein-AM / Propidium iodide (Calcein-AM / PI) with PBS at a ratio of 1:1000 to make a working solution. Add 200 μL of the working solution to each well. Wrap the plate with aluminum foil and place it in a 37°C constant temperature incubator for 30 minutes. Then remove the staining solution, wash it three times with PBS, and finally take pictures using an inverted fluorescence microscope. The specific results are shown in Figure 5 .

[0161] Depend on Figure 5 The in vitro biocompatibility results of core-shell microspheres show that Figure 5As shown in A, ATDC5 showed an obvious proliferation trend as the culture time prolonged; there was no significant difference among the groups on the 5th day of culture. Figure 5 As shown in the fluorescence image of B, after 1 day of culture, there was no significant difference in cell proliferation among the CSM, Rap@CSM, KGN@CSM, and Rap / KGN@CSM groups. On the 3rd day of culture, the number of cells in each group increased significantly, and no obvious signs of dead cells were observed. On the 5th day of culture, the number of cells in each group showed more obvious signs of proliferation, and there was no significant difference in the number of live cells among the groups. The results show that different hydrogel microspheres have good biocompatibility.

[0162] Example 6 Cell apoptosis inhibition and reactive oxygen scavenging effects of drug-loaded core-shell microspheres

[0163] (1) Cell apoptosis inhibition assay: Reactive oxygen species scavenging ATDC5 cells were cultured at 1×10 4 The cells were inoculated into a 24-well cell culture plate at a density of 100 cells per well, and then the cells were pretreated with the above-mentioned culture medium containing the extract for 4 hours, and then IL-1β (10 ng / mL) was added to stimulate the chondrocytes. The apoptosis (TUNEL) detection kit was prepared with a working solution according to a certain ratio. After ATDC5 cells were cultured for 48 hours, the culture medium was discarded, and the cells were washed three times with PBS, stained according to the steps of the kit, and photographed using a fluorescence microscope. The specific results are shown in Figure 6 .

[0164] (2) Detection of reactive oxygen species scavenging ability: ATDC5 cells were cultured at 1×10 5 The cells were inoculated into a 6-well cell culture plate at a density of 100 cells per well, and then the cells were pretreated with the above-mentioned culture medium containing the extract for 4 hours, and then IL-1β (10 ng / mL) was added to stimulate the chondrocytes. The reactive oxygen detection reagent (containing the fluorescent probe DCFH-DA) was prepared into a working solution with serum-free culture medium in a certain proportion. After ATDC5 cells were cultured for 48 hours, the culture medium was discarded, the cells were washed three times with PBS buffer, and then incubated in the dark with the reactive oxygen detection working solution for 30 minutes. Finally, a fluorescence microscope was used for observation and photography. The specific results are shown in Figure 6 .

[0165] Depend on Figure 6 The results of cell apoptosis inhibition and reactive oxygen scavenging performance of drug-loaded core-shell microspheres show that Figure 6 A and Figure 6 As shown in C, after IL-1β treatment, the fluorescence intensity of the group not treated with microsphere extract was the strongest, and the fluorescence intensity of the group treated with microsphere extract was weaker than that of the untreated group. Among them, the fluorescence intensity of the dual-drug-loaded hydrogel microsphere group was the weakest, indicating that the dual-drug-loaded microspheres have the effect of inhibiting cell apoptosis. Figure 6 B and Figure 6The results of D show that the green fluorescence of the group with only inflammatory factor IL-1β is the most obvious, and the green fluorescence of the experimental group treated with hydrogel microsphere extract gradually weakens compared with the IL-1β group alone. Therefore, compared with the IL-1β group, the ROS levels of the IL-1β+Rap@CSM group and the IL-1β+Rap / KGN@CSM group were significantly reduced, indicating that Rap / KGN@CSM microspheres have a certain active oxygen scavenging effect.

[0166] Example 7 Drug-loaded core-shell microspheres inhibit cartilage catabolism

[0167] ATDC5 cells were cultured at 1×10 5 The cells were seeded into 6-well cell culture plates at a density of 100 cells per well, and then the culture medium containing different microsphere extracts was added for pretreatment for 4 hours, and then the culture medium containing IL-1β (10 ng / mL) was added. After 48 hours of culture, RT-qPCR was used to detect the expression of related genes, including type II collagen α1 (COL2α1), matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 13 (MMP13) and thrombospondin a disintegrin metallopeptidase 5 (ADAMTS5) genes, to evaluate the expression levels of genes related to chondrocyte matrix and cartilage matrix degradation.

[0168] Cartilage ECM is mainly composed of type II collagen and aggrecan, which can be degraded by proteases such as MMP9 and ADAMTS5 during the progression of OA. Figure 7 As shown in the figure, after IL-1β treatment alone, the mRNA expression of MMP13, MMP9 and ADAMTS5 in ATDC5 cells was significantly upregulated, while the mRNA expression of COL2α1 was downregulated. As ATDC5 cells were treated with Rap@CSM, KGN@CSM and Rap / KGN@CSM microsphere extracts, the mRNA expression of MMP13, MMP9 and ADAMTS5 in the cells was significantly downregulated, while the mRNA expression of COL2α1 was gradually upregulated, among which the mRNA expression of COL2α1 in the Rap / KGN@CSM group was higher than that in other groups. This indicates that Rap and KGN have a good synergistic effect on OA treatment, can reduce the production of osteoarthritis cartilage matrix decomposition-related factors, and can promote the production of type II collagen. Therefore, Rap / KGN@CSM microspheres have the biological function of effectively inhibiting cartilage decomposition in the inflammatory microenvironment.

[0169] Example 8 Cartilage-promoting effect of drug-loaded core-shell microspheres

[0170] The 3rd to 5th generation BMSCs with good growth status were selected and 1×10 5Each well was inoculated in a 6-well plate. After the cells grew for a certain period of time, they were cultured in chondrogenic induction medium (containing 10% fetal bovine serum, 10 ng / mL TGF-β1, 50 μg / mL ascorbic acid, 10 -7 mol / L dexamethasone, 50mg / mL ITS), and added culture medium containing different microsphere extracts. After 3 and 7 days of culture, RT-qPCR was used to detect the expression of related genes, including Aggrecan, COL2α1, and SOX-9 genes, to evaluate the promotion of BMSCs differentiation into chondrocytes.

[0171] Aggrecan and type II collagen (COL2α1) are important components of hyaline cartilage ECM and can be used as the main detection indicators for in vitro chondrogenic induction culture. Figure 8 As shown in the figure, the expression of chondrogenic genes (Aggrecan, COL2α1, SOX-9) increased with the extension of culture time. On the third day of culture, the mRNA expression levels of Aggrecan, COL2α1, and SOX-9 in the Rap@CSM, KGN@CSM, and Rap / KGN@CSM groups were significantly higher than those in the Control group. As time went on, after the seventh day of culture, the expression levels of Aggrecan, COL2α1, and SOX-9 in the Rap@CSM, KGN@CSM, and Rap / KGN@CSM groups were all upregulated, and the expression level of chondrogenic-related genes in the Rap / KGN@CSM group was better than that in the other groups. The results show that Rap and KGN can play a synergistic role in promoting the chondrogenic differentiation of BMSCs to a certain extent, so Rap / KGN@CSM microspheres have good cartilage regeneration performance.

[0172] Example 9 Effect of drug-loaded core-shell microspheres in the treatment of OA

[0173] The OA model of C57BL / 6J mice was established by anterior cruciate ligament transection (ACLT). The knee joint of mice was selected for surgery. A longitudinal surgical incision was made on the inner edge of the patella. The skin and subcutaneous tissue were cut in sequence to fully expose and open the joint capsule. The anterior cruciate ligament was severed with a surgical knife. Then the joint capsule and the surrounding skin were sutured, and the drawer test was used to confirm that the anterior cruciate ligament had been completely severed. The control group (Sham) was a sham operation group, and no treatment was performed on the anterior cruciate ligament. One week after the operation, the normal operation group was randomly divided into 5 groups, and PBS, CSM, Rap@CSM, KGN@CSM and Rap / KGN@CSM were injected into the joint cavity at a dose of 100μL. The first injection was performed in the first week after modeling, and then once every four weeks. After the 8th week of treatment, the knee joint samples of mice were obtained, and X-ray and micro-CT scans were performed, and the osteophyte volume and bone mineral density (BMD) were analyzed. Histological staining, including H&E staining and safranin-fast green staining, was performed on tissue sections to evaluate cartilage repair.

[0174] To evaluate the changes in articular cartilage, the articular cartilage of mice was observed using X-ray and micro-CT, and parameters such as osteophyte volume and bone density were analyzed ( Fig. 9 ). Compared with the Sham group, the joint space of the PBS and CSM groups was significantly narrowed, followed by the Rap@CSM, KGN@CSM and Rap / KGN@CSM groups, and the joint space of the Rap / KGN@CSM group was closest to that of the Sham group. The clinical manifestations of osteoarthritis include narrowing of the joint space, so the Rap / KGN@CSM group showed better therapeutic effects. In addition, the PBS group showed obvious osteophyte formation, and a small amount of osteophytes were also observed in the Rap@CSM and KGN@CSM groups, while the Rap / KGN@CSM group had improved joint morphology and fewer osteophytes, indicating that Rap / KGN@CSM microspheres can delay OA cartilage degeneration. The changes in articular cartilage after the treatment of OA with drug-loaded core-shell microspheres were observed by H&E and safranin-fast green staining ( Fig.10 ). In the PBS group, cartilage was severely worn and clearly deformed, indicating that the articular cartilage lesions were serious. In addition, the CSM group also showed obvious cartilage wear, while the cartilage damage in the Rap@CSM and KGN@CSM groups was milder than that in the PBS group. The cartilage surface damage in the Rap / KGN@CSM group was lower, and the articular cartilage was more complete and smooth. These results show that the dual-drug loaded microspheres Rap / KGN@CSM that continuously release Rap and KGN can inhibit OA cartilage degeneration and provide an effective strategy for the treatment of osteoarthritis.

[0175] In summary, the present invention provides a drug-loaded core-shell microsphere that regulates cell autophagy and chondrogenesis, and its preparation method and application, which improves the retention time and bioavailability of the drug in the joint cavity, effectively improves the activity of chondrocytes and promotes cartilage repair. Therefore, the present invention effectively overcomes the various shortcomings of the prior art and has a high industrial utilization value.

[0176] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. A drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, characterized in that: From the outside to the inside, a shell layer and a core layer are arranged in sequence, wherein the shell layer comprises a polymer matrix with photo-crosslinking properties and first drug-loaded nanoparticles loaded with drugs for regulating chondrocyte autophagy activity, and the core layer comprises a water-soluble polymer matrix, targeted cartilage matrix molecular modification and second drug-loaded nanoparticles loaded with drugs for promoting chondrogenesis, and the release rate of the drugs for regulating chondrocyte autophagy activity is faster than the release rate of the drugs for promoting chondrogenesis.

2. The drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 1, characterized in that: Includes any one or more of the following conditions: A1) in the shell layer, the polymer matrix having photo-crosslinking properties is selected from at least one of methacrylated gelatin, methacrylated hyaluronic acid, methacrylated silk fibroin, methacrylated chondroitin sulfate, methacrylated polylysine, methacrylated polyarginine, and methacrylated polyglutamic acid; A2) in the shell layer, a photoinitiator is added to the polymer matrix having photo-crosslinking properties; A3) in the shell layer, the first drug-loaded nanoparticles are selected from at least one of mesoporous silica nanoparticles, mesoporous manganese dioxide nanoparticles, mesoporous polydopamine, metal organic frameworks, conjugated organic frameworks, and polylactic acid-co-glycolic acid nanoparticles; A4) in the shell layer, the drug regulating chondrocyte autophagy activity is selected from at least one of rapamycin, pravastatin, metformin, α-ketoglutaric acid, and artemisinin; A5) in the shell layer, the weight ratio of the photo-crosslinking polymer matrix to the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity is 10-200:1-100; A6) in the core layer, the water-soluble polymer matrix is ​​selected from at least one of methylcellulose, carboxymethyl chitosan, sodium alginate and hyaluronic acid; A7) In the nuclear layer, the second drug-loaded nanoparticles are modified with targeted cartilage matrix molecules; preferably, the targeted cartilage matrix molecules modified with the second drug-loaded nanoparticles are selected from at least one of type II collagen targeting peptides and cationic polypeptides; A8) in the nuclear layer, the second drug-loaded nanoparticles are selected from at least one of liposomes, polymer vesicles, and exosomes; A9) in the nuclear layer, the cartilage-promoting drug is selected from at least one of KGN, chondroitin sulfate, transforming growth factor-β, and icariin; A10) in the core layer, the weight ratio of the water-soluble polymer matrix to the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with a chondrogenesis-promoting drug is 10-150:1-100; A11) In the core layer, the weight ratio of the water-soluble polymer matrix to the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with a chondrogenesis-promoting drug is 10-150:1-100.

3. The drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 2, characterized in that: Includes any one or more of the following conditions: A201) The photoinitiator is phenyl (2,4,6-trimethylbenzoyl) lithium phosphate; A202) the weight ratio of the photoinitiator to the photocrosslinkable polymer matrix is ​​1-10:10-200; A501) the weight ratio of the first drug-loaded nanoparticles to the loaded drug for regulating chondrocyte autophagy activity is 100:1-50; A701) The type II collagen targeting peptide is WYRGRL, with an amino acid sequence of tryptophan-tyrosine-arginine-glycine-arginine-leucine; A702) the cationic polypeptide is selected from at least one of poly-lysine and poly-arginine; A703) the weight ratio of the second drug-loaded nanoparticles to the modified targeted cartilage matrix molecules is 100:1-20; A901) The weight ratio of the second drug-loaded nanoparticles to the loaded chondrogenesis-promoting drug is 100:1-20.

4. A method for preparing drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis, comprising the following steps: 1) loading a drug that regulates chondrocyte autophagy activity into a first drug-loaded nanoparticle, and uniformly mixing the obtained first drug-loaded nanoparticle loaded with the drug that regulates chondrocyte autophagy activity with a polymer matrix having photo-crosslinking properties in a solvent to obtain a shell layer solution; and / or, modifying a second drug-loaded nanoparticle with targeted cartilage matrix molecules, and loading a chondrogenesis drug into the second drug-loaded nanoparticle, and uniformly mixing the obtained second drug-loaded nanoparticle modified with targeted cartilage matrix molecules and loaded with a chondrogenesis-promoting drug with a water-soluble polymer matrix in a solvent to obtain a core layer solution; 2) using a microfluidic chip, respectively passing a shell layer solution and a core layer solution into different flow channels to form a shell layer channel and a core layer channel, then mixing the shell layer solution in the shell layer channel with the core layer solution in the core layer channel to form a core-shell solution located in a continuous phase channel, and passing an oily substance into the continuous phase channel to form a double-layer structure microsphere having a shell layer and a core layer in sequence from the outside to the inside of the core-shell solution, so that the release rate of the drug regulating the autophagy activity of chondrocytes in the shell layer solution is faster than the release rate of the drug promoting chondrogenesis in the core layer solution; 3) The double-layer structure microspheres are irradiated with a blue light source for photocuring to provide drug-loaded core-shell microspheres.

5. The method for preparing drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 4, characterized in that: In step 1), any one or more of the following conditions are included: B1) The drug for regulating chondrocyte autophagy activity is loaded in the first drug-loaded nanoparticles, comprising: dissolving the first drug-loaded nanoparticles and the drug for regulating chondrocyte autophagy activity in a first solvent and stirring, collecting the drug-loaded nanoparticles by centrifugation, washing with a second solvent, and centrifuging again to obtain the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity; B2) The concentration of the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity is 0.1-100 mg / mL; B3) The concentration of the polymer matrix containing photo-crosslinking properties is 1-200 mg / mL; B4) the weight ratio of the first drug-loaded nanoparticles loaded with the drug for regulating chondrocyte autophagy activity to the polymer matrix having photo-crosslinking properties is 0.1-100:1-200; B5) the targeted cartilage matrix molecule is selected from at least one of type II collagen targeting peptides and cationic polypeptides; B6) the second drug-loaded nanoparticle is selected from at least one of liposomes, polymer vesicles, and exosomes; B7) the cartilage-promoting drug is selected from at least one of KGN, chondroitin sulfate, transforming growth factor-β, and icariin; B8) modifying the second drug-loaded nanoparticles with targeted cartilage matrix molecules and loading the chondrogenesis drug into the second drug-loaded nanoparticles, including: dissolving the targeted cartilage matrix molecules, the chondrogenesis drug and the second drug-loaded nanoparticles in a third solvent, performing rotary evaporation and resuspending to obtain the desired second drug-loaded nanoparticles modified with targeted cartilage matrix molecules and loaded with the chondrogenesis-promoting drug; B9) the concentration of the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with the drug for promoting chondrogenesis is 0.1 to 100 mg / mL; B10) the concentration of the water-soluble polymer matrix is ​​1 to 150 mg / mL; B11) the weight ratio of the second drug-loaded nanoparticles targeted for cartilage matrix molecule modification and loaded with the drug for promoting cartilage formation to the water-soluble polymer matrix is ​​0.1-100:1-150; B12) the solvent is water or phosphate buffer; B13) the amount of solvent added to the shell solution is 1-10 mL; B14) the amount of solvent added to the core layer solution is 1-10 mL; B15) The uniform mixing can be achieved by continuous stirring, and the stirring conditions are: a rotation speed of 10-500 rpm; a stirring time of 0.5-24 hours; and a temperature of 15-45°C.

6. The method for preparing drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 5, characterized in that: Includes any one or more of the following conditions: B101) the first drug-loaded nanoparticles are selected from at least one of mesoporous silica nanoparticles, mesoporous manganese dioxide nanoparticles, mesoporous polydopamine, metal organic frameworks, conjugated organic frameworks, and polylactic acid-co-glycolic acid nanoparticles; B102) the drug regulating chondrocyte autophagy activity is selected from at least one of rapamycin, pravastatin, metformin, α-ketoglutaric acid, and artemisinin; B103) the weight ratio of the first drug-loaded nanoparticles to the drug for regulating chondrocyte autophagy activity is 100:1-50; B104) the first solvent is selected from at least one of anhydrous ethanol, water or phosphate buffer; B105) the ratio of the added weight of the first drug-loaded nanoparticles to the added volume of the first solvent is 5-20:1-5, mg / mL; B106) the stirring is carried out at room temperature under light-proof conditions; B107) the stirring is 6-48 hours; B108) the second solvent is selected from at least one of a 5-15% aqueous ethanol solution, water or a phosphate buffer solution; B109) The number of washings is 1-3 times; B110) The centrifugal conditions are: a centrifugal speed of 2000-10000 rpm and a centrifugal time of 3-20 minutes; B501) The type II collagen targeting peptide is WYRGRL, with an amino acid sequence of tryptophan-tyrosine-arginine-glycine-arginine-leucine; B502) the cationic polypeptide is selected from at least one of poly-lysine and poly-arginine; B601) the second drug-loaded nanoparticle is a liposome; the liposome comprises lecithin, cholesterol and octadecylamine, and the weight ratio of the lecithin, cholesterol and octadecylamine is 400:3-5:35-45; B801) The weight ratio of the targeted cartilage matrix molecule to the second drug-loaded nanoparticle is 30-50:300-500; B802) the weight ratio of the chondrogenic drug to the second drug-loaded nanoparticles is 5-20:300-500; B803) the third solvent is selected from at least one of anhydrous ethanol, water or phosphate buffer; B804) the ratio of the volume of the third solvent to the weight of the second drug-loaded nanoparticles is 1-20:300-500, mL / mg; B805) the rotary evaporation temperature is 30-50°C; the rotary evaporation time is 10-30 minutes; B806) the resuspending comprises adding a fourth solvent to the lipid film obtained by rotary evaporation for hydration, stirring, ultrasonicating, and filtering the obtained liposome suspension; preferably, the fourth solvent is selected from at least one of water or phosphate buffer, and the ratio of the volume of the fourth solvent to the weight of the second drug-loaded nanoparticles is 5-20:300-500, mL / mg; B121) The water is ultrapure water; B122) The phosphate buffer is PBS buffer, pH = 7.2-7.

5.

7. The method for preparing drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 4, characterized in that: In step 2), any one or more of the following conditions are included: C1) The measurement conditions of the microfluidic chip are as follows: the flow rate of the water phase in the core layer is 0.1-50 μL / min; the flow rate of the water phase in the shell layer is 0.1-100 μL / min; the flow rate of the oil phase is 1-200 μL / min, so that the release rate of the drug regulating the autophagy activity of chondrocytes in the shell layer solution is faster than the release rate of the drug promoting cartilage formation in the core layer solution; C2) The oily substance is mineral oil containing Span 80; the concentration of Span 80 in the mineral oil is 1-100 mg / mL.

8. The method for preparing drug-loaded core-shell microspheres for sequentially regulating cell autophagy and chondrogenesis according to claim 4, characterized in that: In step 3), any one or more of the following conditions are included: D1) The wavelength of the blue light source is 400-410nm; D2) the light curing treatment time is 10-60s; D3) After the light curing treatment, washing and centrifugation are performed to obtain the precipitate to obtain the drug-loaded core-shell microspheres; D4) the particle size of the drug-loaded core-shell microspheres is 10 to 500 μm; D5) the core layer thickness of the drug-loaded core-shell microspheres is 5 to 200 μm; D6) The shell thickness of the drug-loaded core-shell microspheres is 5 to 300 μm.

9. A drug-loaded core-shell microsphere for sequentially regulating cell autophagy and chondrogenesis, prepared by the method according to any one of claims 4 to 8.

10. Use of the drug-loaded core-shell microspheres with a sequence regulating cell autophagy and chondrogenesis according to any one of claims 1 to 3 or 9 in the preparation of a drug for treating osteoarthritis cartilage degeneration diseases.

Citation Information

Cited By

  • Magnetic resonance nanometer diagnosis system for accurately identifying multidrug resistance of lung cancer

    CN117470893A

  • A magnetic resonance nanodiagnostic system for accurately identifying lung cancer multidrug resistance

    CN117470893B

  • Microneedle for treating periodontitis as well as preparation method and application of microneedle

    CN119587521A

  • Bifunctional cellulose porous chromatographic medium, preparation method thereof and exosome enrichment method

    CN121244183A

  • A bifunctional cellulose porous chromatography medium, a preparation method thereof and an exosome enrichment method

    CN121244183B